If you have fallen a victim to modern-day living, and you feel tense on your shoulders, don't panic - you are not alone.

There are many things to worry about these days, including relationships, politics, and the COVID pandemic, making anxiety and other mental conditions become hosts of the modern individual. Life can unnoticeably turn into a nail-biting marathon caused by your nerves, stress, and tension.

Luckily, there are loads of remedies out there, and some of them are developed by Cingulate Therapeutics. Founded back in 2012, in Kansas City, Cingulate Therapeutics is a highly renowned biopharmaceutical company that develops products for mental health disorders with a primary focus on ADHD.

But how experienced are the members of the management, and what does Cingulate include in their program?

Stick around and learn all the bits and pieces about the 4 guys that stand behind Cingulate Therapeutics, minimizing the hassle of every day, one remedy at a time.

Cingulate Therapeutics - the Powerhouse

With Craig Gilgallon, Matthew Brams, Raul Silva, and Shane J. Schaffer behind the steering wheel, Cingulate Therapeutics aims to help people facing anxiety conditions manage their daily lives without experiencing downfalls. But, let’s see who these experts are, and why did they come together to work on such a delicate area of mental disorders.

Craig S. Gilgallon is the engine of Cingulate Therapeutics. Besides being the co-founder of Cingulate, Craig also works as General Counsel, managing and directing all the company’s legal requirements.

He has over 10 years of experience in corporate law and has also represented and advised clients from early-stage to mid and large-sized multinationals in several types of transactions, such as acquisitions, mergers, divestitures, restructurings, corporate recapitalizations.

Craig holds a bachelor’s degree from Ithaca College and has his Juris doctorate from the prestigious Thomas Jefferson School of Law. Next in line is the expert in ADHD - Matthew Brams. Dr. Matthew is also a co-founder of Cingulate Therapeutics and is a member of the Board of Directors. He is a medical director, as well as Principal of Bayou City Research Inc. Matthew has published over 20 journal articles so far and is a highly appreciated clinical assistant professor at the Baylor College of Medicine.

He has also been a chief investigator in various pivotal trials, including drugs in bipolar disorder, ADHD, schizophrenia, and autism therapeutic areas. In addition, he has more than 25 years of experience in Adult and Child Psychiatry with expertise in ADHD and ASD (Autistic Spectrum Disorders).

Raul R. Silva works as CSO and is a co-founder of Cingulate Therapeutics. Raul holds a medical degree from Ross University and is a practicing adolescent and child psychiatry. Raul works as an assistant professor at the New York University School of Medicine. Before that, Raul was the deputy manager in the Division of Adolescent and Child Psychiatry at Bellevue Hospital Center in New York City.

Dr. Raul is a proud author of more than 125 publications and has been guest-starring at national meetings on over 120 occasions.

Shane J. Schaffer, a co-founder, chairman, and CEO at Cingulate Therapeutics, holds a degree of Doctor of Pharmacy from the University of Kansas, boasting a 25-year pharmaceutical industry career. As an outstanding veteran in this area, Shane has garnered affluent experience in drug development. In the past, Shane has worked for Sanofi, Novartis, and Pfizer.

Shane is proud of his comprehensive therapeutic expertise covering the commercialization and development of various billion-dollar products such as the ADHD Franchise of Ritalin & Focalin, Hyalgan, Lipitor, Arixtra, Lyrica, Avapro/Avalide, and Eligard.

The four co-founders, each with their own drive and expertise, joined forces to devise a company that’ll cobblestone the path towards future drug delivery.

Detangling the Web Around ADHD

Cingulate Therapeutics Company was established as a company to offer a decent life for patients with various mental conditions and to provide them with an opportunity to experience life without the downfalls caused by certain disorders.

This powerful biopharmaceutical company uses PTR or Precision Timed Release, which is modern drug supply platform technology.

Creating and developing a pipeline of future-generation pharmaceutical brands to improve the daily activities of patients facing diagnosed conditions, is the company’s primary aim. Cingulate Therapeutics’ MO revolves around heavy daily dosing programs and suboptimal treatment effects.

Cingulate Therapeutics primarily focuses on the treatment of ADHD (Attention-Deficit/Hyperactivity Disorder).

The company’s innovative PTR platform technology incorporates a branded EBL, or Erosion Barrier Layer, designed to enable the release of medicine substances at precise pre-defined time intervals, demonstrating the potential for once-a-day multi-dose drugs.

The company initially targets the ADHD stimulant-treatment market, which comes with market size of $15.3 billion in the U.S. Doctors often prescribe stimulant drugs for treating ADHD, and over 90% of all prescribed ADHD medications are in the United States.

Reshaping the Drug Prescription Mould

Shane, Craig, Raul, and Matthew went far and beyond to modify the way treating ADHD had worked thus far. Thanks to the founders’ expertise in different realms, Cingulate Therapeutics managed to do something to alleviate the burden of living with mental conditions like ADHD.

We’re about to get more professional and use a niche-adequate lingo in describing what medical marvel has Matthew, Craig, Shane, and Raul’s company brought to light.

Cingulate Therapeutics offers two exclusive first-line stimulant drugs: dexmethylphenidate (CTx-1301) and dextroamphetamine (CTx-1302). They are developed as a treatment for ADHD in the 3 core patient groups: adults (18+), adolescents (13 to 17 years old), and children (between 6 and 12 years).

Both stimulants CTx-1301 and CTx-1302 are created to address the crucial shortcomings of already approved stimulant remedies. Some of the key points the stimulants target offer a direct onset of action (within half an hour); provide complete active day interval, and eliminate the necessity for a recovery/booster dose of short-term acting stimulant treatments.

Also, Cingulate Therapeutics proudly states that the stimulants eliminate or minimize the crash/rebound symptoms linked to early drugs ‘wear-off’ and offer promising tolerability with a precise descent of medication blood levels.

By getting rid of the not-so-popular ‘booster’ dose that is recommended for up to 60% of patients with ADHD with their regular medication, Cingulate Therapeutics believes that its product candidates are powerful enough to offer significant practical and societal benefits.

Some of the perks of using the stimulants include decreasing the diversion and abuse related to short-time-acting stimulant treatments, allowing doctors to prescribe 1 medication instead of 2, offering patients to spend less money on prescriptions since they only need to pay for 1 drug instead of for 2.

Fortifying the Finances

Being a successful company means finances are more than needed, especially in the drug-development business. To achieve financial stability, Cingulate Therapeutics went through 3 venture rounds, raising $7.5 million with the latest one in 2018, by investor Werth Family Investment Associates.

After deciding it was high time to present the company to the general public, stock-wise, Cingulate Therapeutics increased its IPO value from 3.57 million to 4.17 million shares at the beginning of this month, or more precisely on Dec. 7, 2021

It warrants to purchase 4.17 million shares of shared stock and estimated the IPO at $6, which is the lowest end of the $6-to-$8 price range. However, the IPO raised $25.02 million. The warrants were forecasted to trade under the mark “CINGW” and the stock to trade under the figure “CING”, on NASDAQ, on Wednesday, Dec. 8, 2021.

Cingulate Therapeutics’ value raised and exceeded a whopping $24.99 million. Previously, the company had postponed the IPO, which had been projected to begin in the middle of October 2021. 3 days earlier, on October 12, 2021, the company cut the volume of its IPO to 4.44 million shares. It also reduced the worth from $10-$12 range to $8 to $10, to raise $39.96 million.

As it gets closer to Christmas, the price of the Cingulate Therapeutics stock value is decreasing and is currently as low as $2.71, with a market cap of $27.75 million.

Enlightening the Future of Therapeutics

Before the guaranteed commissions and discounts, as well as estimated costs, the net proceeds for the company are expected to be around $25 million. The company plans to use the gross proceeds for further development and research for its products.

However, before garnering the trust of a myriad of patients, medical professionals, and companies in the medical business, Craig, Matthew, Raul, and Shane’s company had to stand tall in the face of competition coming from companies like InteKrin Therapeutics, Minerva Neurosciences, and TorreyPines Therapeutics, among others.

Today, the company is headquartered in Kansas, with an office in New Jersey, as well, employing around 70 people.

Cingulate Therapeutics intends to spend the profit on pre-commercialization development of CTx-1301, continuous development and research of CTx-1302, proof of model study for CTx-2103, to please obligations under definitely related party notes, to meet outstanding accumulated payroll costs to company employees, covering their executive officers.

The company also plans to pay for working capital, expenses, and general company purposes, such as further investing in necessary research and project development efforts.

With a company like Cingulate Therapeutics, tackling the issues of mental conditions might just become a bearable bundle of challenges.